Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Luis Bruno Blanch is active.

Publication


Featured researches published by Luis Bruno Blanch.


Chemical Biology & Drug Design | 2011

Synthesis of 2-Hydrazolyl-4-Thiazolidinones Based on Multicomponent Reactions and Biological Evaluation Against Trypanosoma Cruzi

Chiara Pizzo; Cecilia Saiz; Alan Talevi; Luciana Gavernet; Pablo H. Palestro; Carolina L. Bellera; Luis Bruno Blanch; Diego Benítez; Juan José Cazzulo; Agustina Chidichimo; Peter Wipf; S. Graciela Mahler

A series of 18 novel 2‐hydrazolyl‐4‐thiazolidinones‐5‐carboxylic acids, amides and 5,6‐α,β‐unsaturated esters were synthesized, and their in vitro activity on cruzipain and T. cruzi epimastigotes was determined. Some agents show activity at 37 μm concentration in the enzyme assay. Computational tools and docking were used to correlate the biological response with the physicochemical parameters of the compounds and their cruzipain inhibitory effects.


BioMed Research International | 2014

Docking Applied to the Prediction of the Affinity of Compounds to P-Glycoprotein

Pablo H. Palestro; Luciana Gavernet; Guillermina Estiu; Luis Bruno Blanch

P-glycoprotein (P-gp) is involved in the transport of xenobiotic compounds and responsible for the decrease of the drug accumulation in multi-drug-resistant cells. In this investigation we compare several docking algorithms in order to find the conditions that are able to discriminate between P-gp binders and nonbinders. We built a comprehensive dataset of binders and nonbinders based on a careful analysis of the experimental data available in the literature, trying to overcome the discrepancy noticeable in the experimental results. We found that Autodock Vina flexible docking is the best choice for the tested options. The results will be useful to filter virtual screening results in the rational design of new drugs that are not expected to be expelled by P-gp.


Bioorganic & Medicinal Chemistry | 2013

Inhibition pattern of sulfamide-related compounds in binding to carbonic anhydrase isoforms I, II, VII, XII and XIV.

Luciana Gavernet; Jose L. Gonzalez Funes; Pablo H. Palestro; Luis Bruno Blanch; Guillermina Estiu; Alfonso Maresca; Ivana Barrios; Claudiu T. Supuran

A set of sulfamides and sulfamates were synthesized and tested against several isoforms of carbonic anhydrase: CA I, CA II, CA VII, CA XII and CA XIV. The biological assays showed a broad range of inhibitory activity, and interesting results were found for several compounds in terms of activity (Ki <1μm) and selectivity: some aromatic sulfamides are active against CA I, CA II and/or CA VII; while they are less active in CA XII and CA XIV. On the other hand, bulky sulfamides are selective to CA VII. To understand the origin of the different inhibitory activity against each isozyme we used molecular modeling techniques such as docking and molecular dynamic simulations.


Journal of Chemical Information and Modeling | 2010

Affinity of sulfamates and sulfamides to carbonic anhydrase II isoform: experimental and molecular modeling approaches.

Luciana Gavernet; Jose L. Gonzalez Funes; Luis Bruno Blanch; Guillermina Estiu; Alfonso Maresca; Claudiu T. Supuran

Sixteen aromatic and aliphatic sulfamides and sulfamates were synthesized and tested in their inhibition to carbonic anhydrase CAII activity. The weaker inhibition pattern shown by sulfamides as compared to sulfamates is interpreted in this research by means of molecular modeling techniques, including known inhibitors (topiramate and its sulfamide cognate) in the analysis. The results nicely explain the origin of the inhibitory activity, which is not only related to positive interactions of the ligand with the active site residues but also to the solvation pattern characteristic of each ligand.


PLOS ONE | 2014

Targeting a Cross-Reactive Gly m 5 Soy Peptide as Responsible for Hypersensitivity Reactions in a Milk Allergy Mouse Model

Renata Curciarello; Paola Smaldini; Ángela María Candreva; Virginia González; Gustavo Parisi; Ana Cauerhff; Ivana Barrios; Luis Bruno Blanch; Carlos A. Fossati; Silvana Petruccelli; Guillermo H. Docena

Background Cross-reactivity between soybean allergens and bovine caseins has been previously reported. In this study we aimed to map epitopes of the major soybean allergen Gly m 5 that are co-recognized by casein specific antibodies, and to identify a peptide responsible for the cross-reactivity. Methods Cows milk protein (CMP)-specific antibodies were used in different immunoassays (immunoblotting, ELISA, ELISA inhibition test) to evaluate the in vitro recognition of soybean proteins (SP). Recombinant Gly m 5 (α), a truncated fragment containing the C-terminal domain (α-T) and peptides of α-T were obtained and epitope mapping was performed with an overlapping peptide assay. Bioinformatics tools were used for epitope prediction by sequence alignment, and for modelling the cross-recognized soy proteins and peptides. The binding of SP to a monoclonal antibody was studied by surface Plasmon resonance (SPR). Finally, the in vivo cross-recognition of SP was assessed in a mouse model of milk allergy. Results Both α and α-T reacted with the different CMP-specific antibodies. α-T contains IgG and IgE epitopes in several peptides, particularly in the peptide named PA. Besides, we found similar values of association and dissociation constants between the α-casein specific mAb and the different milk and soy components. The food allergy mouse model showed that SP and PA contain the cross-reactive B and T epitopes, which triggered hypersensitivity reactions and a Th2-mediated response on CMP-sensitized mice. Conclusions Gly m 5 is a cross-reactive soy allergen and the α-T portion of the molecule contains IgG and IgE immunodominant epitopes, confined to PA, a region with enough conformation to be bound by antibodies. These findings contribute to explain the intolerance to SP observed in IgE-mediated CMA patients, primarily not sensitised to SP, as well as it sets the basis to propose a mucosal immunotherapy for milk allergy using this soy peptide.


European Journal of Pharmacology | 2016

Novel sulfamides and sulfamates derived from amino esters: Synthetic studies and anticonvulsant activity

María Luisa Villalba; Andrea V. Enrique; Josefina Higgs; Rocío Castaño; Sofía Goicoechea; Facundo Taborda; Luciana Gavernet; Ileana D. Lick; Mariel Marder; Luis Bruno Blanch

We report herein the design and optimization of a novel series of sulfamides and sulfamates derived from amino esters with anticonvulsant properties. The structures were designed based on the pharmacophoric pattern previously proposed, with the aim of improving the anticonvulsant action. The compounds were obtained by a new synthetic procedure with microwave assisted heating and the use of adsorbents in the isolation process. All the derivatives showed protection against the maximal electroshock seizure test (MES test) in mice at the lowest dose tested (30 mg/kg) but they did not show significant protection against the chemical induced convulsion by pentylenetetrazole. These results verify the ability of the computational model for designing new anticonvulsants structures with anti-MES activity. Additionally, we evaluated the capacity of the synthesized structures to bind to the benzodiazepine binding site (BDZ-bs) of the γ-aminobutiric acid receptor (GABAA receptor). Some of them showed medium to low affinity for the BDZ-bs.


Archive | 2012

Recent Trends on QSAR in the Pharmaceutical Perceptions

Mahmud Tareq Hassan Khan; Concepción Abad; Speranta Avram; Florin Borcan; Fernanda Borges; Luis Bruno Blanch; Catalin Buiu; Bogdan Bumbacila; Gerardo M. Casañola-Martín; Eduardo A. Castro; Rodica Cinca; M. Natália D. S. Cordeiro; Maykel Cruz-Monteagudo; Mukesh Doble; Corina Duda-Seiman; Daniel Duda-Seiman; Wael M. Elshemey; Seiichiro Fujisawa; Luciana Gavernet; Humberto González-Díaz; Aliuska Morales Helguera; Medhat Ibrahim; Yoshinori Kadoma; Huong Le-Thi-Thu; Feng Luan; Ole Lund; Claus Lundegaard; Yovani Marrero-Ponce; Dan Mihailescu; Cristian R. Munteanu

Description: Quantitative Structure-Activity Relationship (QSAR) is a field where true multidisciplinary approaches are being used. This volume titled Recent Trends on QSAR in the Pharmaceutical Perceptions offers an overview on the latest advancements in the field. The e-book explains both basic approaches and new approaches and ideas in QSAR research, providing readers with an impression of recent inclinations and advances in different aspects of the QSAR strategies, such as descriptors, methods of modeling and validation. This e-book is a valuable reference for pharmacologists, medicinal chemists, drug designers, biotechnologists and industry (pharmaceutical and chemical) professionals. It should serve as an important reference material to stimulate interactions and bridge the gap between participants in academia and industries.


Epilepsy Research | 2017

New model of pharmacoresistant seizures induced by 3-mercaptopropionic acid in mice.

Andrea Enrique; Sofía Goicoechea; Rocío Castaño; Facundo Taborda; Luisa Rocha; Sandra Orozco; Elena Girardi; Luis Bruno Blanch

About 30% of the patients with epilepsy do not respond to clinically established anticonvulsants, despite having effective concentrations of the antiepileptic drug in plasma. Therefore, new preclinical models of epilepsy are needed to identify more efficacious treatments. We describe here a new drug-resistant seizure model in mice to be used at the early stages of pre-clinical trials. This model consists in inducing daily generalized seizures for 23 consecutive days by administration of 3-mercaptopropionic acid (MP). As a result, 100% of animals become resistant to phenytoin and 80% to phenobarbital. Such resistance is strongly associated with the overexpression of P-glycoprotein (Pgp), observed in cerebral cortex, hippocampus and striatum while resistance to Pgp nonsubstrate drugs such as carbamazepine, diazepam and levetiracetam is not observed. This model could be useful for screening novel anticonvulsant drugs with a potential effect on pharmacoresistant seizures treatment.


Bioorganic & Medicinal Chemistry | 2001

Molecular modeling and QSAR analysis of the interaction of flavone derivatives with the benzodiazepine binding site of the GABAA receptor complex

Mariel Marder; G.L. Estiú; Luis Bruno Blanch; Haydee Viola; Cristina Wasowski; Jorge H. Medina; Alejandro C. Paladini


Bioorganic & Medicinal Chemistry | 2016

Sulfamide derivatives with selective carbonic anhydrase VII inhibitory action

María Luisa Villalba; Pablo H. Palestro; Mariangela Ceruso; Jose L. Gonzalez Funes; Alan Talevi; Luis Bruno Blanch; Claudiu T. Supuran; Luciana Gavernet

Collaboration


Dive into the Luis Bruno Blanch's collaboration.

Top Co-Authors

Avatar

Luciana Gavernet

National University of La Plata

View shared research outputs
Top Co-Authors

Avatar

Alan Talevi

National University of La Plata

View shared research outputs
Top Co-Authors

Avatar

Pablo H. Palestro

National University of La Plata

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jose L. Gonzalez Funes

National University of La Plata

View shared research outputs
Top Co-Authors

Avatar

María Luisa Villalba

National University of La Plata

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Andrea V. Enrique

National University of La Plata

View shared research outputs
Top Co-Authors

Avatar

Carolina L. Bellera

National University of La Plata

View shared research outputs
Top Co-Authors

Avatar

Eduardo A. Castro

National Scientific and Technical Research Council

View shared research outputs
Researchain Logo
Decentralizing Knowledge